A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β-amyloid load in an AD cohort

Steve Pedrini, Veer B. Gupta, Eugene Hone, James Doecke, Sid O'Bryant, Ian James, Ashley I. Bush, Christopher C. Rowe, Victor L. Villemagne, David Ames, Colin L. Masters, Ralph N. Martins, Greg Savage, Bill Wilson, Pierrick Bourgeat, Jurgen Fripp, Simon Gibson, Hugo Leroux, Simon McBride, Olivier SalvadoMichael Fenech, Maxime Francois, Mary Barnes, Jenalle Baker, Kevin Barnham, Shayne Bellingham, Julia Bomke, Sveltana Bozin Pejoska, Rachel Buckley, Lesley Cheng, Steven Collins, Ian Cooke, Elizabeth Cyarto, David Darby, Vincent Dore, Denise El-Sheikh, Noel Faux, Christopher Fowler, Karra Harrington, Andy Hill, Malcolm Horne, Gareth Jones, Adrian Kamer, Neil Killeen, Hannah Korrel, Fiona Lamb, Nicola Lautenschlager, Kate Lennon, Qiao Xin Li, Yen Ying Lim, Andrea Louey, Lance Macaulay, Lucy Mackintosh, Paul Maruff, Alissandra McIlroy, Julie Nigro, Kayla Perez, Kelly Pertile, Carolina Restrepo, Barbara Rita Cardoso, Alan Rembach, Blaine Roberts, Jo Robertson, Rebecca Rumble, Tim Ryan, Jack Sach, Brendan Silbert, Christine Thai, Brett Trounson, Irene Volitakis, Michael Vovos, Larry Ward, Andrew Watt, Rob Williams, Michael Woodward, Paul Yates, Fernanda Yevenes Ugarte, Ping Zhang, Sabine Bird, Belinda Brown, Samantha Burnham, Pratishtha Chatterjee, Kay Cox, Shane Fernandez, Binosha Fernando, Sam Gardener, Simon Laws, Florence Lim, Lucy Lim, Michelle Tegg, Kathy Lucas, Georgia Martins, Tenielle Porter, Stephanie Rainey-Smith, Mark Rodrigues, Kaikai Shen, Harmid Sohrabi, Kevin Taddei, Tania Taddei, Sherilyn Tan, Giuseppe Verdile, Mike Weinborn, Maree Farrow, Shaun Frost, David Hanson, Maryam Hor, Yogi Kanagasingam, Wayne Leifert, Linda Lockett, Malcolm Riley, Ian Saunders, Philip Thomas

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Alzheimer's Disease (AD) is the most common form of dementia, characterised by extracellular amyloid deposition as plaques and intracellular neurofibrillary tangles of tau protein. As no current clinical test can diagnose individuals at risk of developing AD, the aim of this project is to evaluate a blood-based biomarker panel to identify individuals who carry this risk. We analysed the levels of 22 biomarkers in clinically classified healthy controls (HC), mild cognitive impairment (MCI) and Alzheimer's participants from the well characterised Australian Imaging, Biomarker and Lifestyle (AIBL) study of aging. High levels of IL-10 and IL-12/23p40 were significantly associated with amyloid deposition in HC, suggesting that these two biomarkers might be used to detect at risk individuals. Additionally, other biomarkers (Eotaxin-3, Leptin, PYY) exhibited altered levels in AD participants possessing the APOE ϵ4 allele. This suggests that the physiology of some potential biomarkers may be altered in AD due to the APOE ϵ4 allele, a major risk factor for AD. Taken together, these data highlight several potential biomarkers that can be used in a blood-based panel to allow earlier identification of individuals at risk of developing AD and/or early stage AD for which current therapies may be more beneficial.

Original languageEnglish
Article number14057
JournalScientific Reports
Volume7
Issue number1
DOIs
StatePublished - 1 Dec 2017

Fingerprint

Dive into the research topics of 'A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β-amyloid load in an AD cohort'. Together they form a unique fingerprint.

Cite this